US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Oxcia AB Publishes Annual Report for 2025

Oxcia AB (publ) (“Oxcia”) today announced the publication of its Annual Report for 2025. Oxcia’s Annual Report is available (in swedish) at https://oxcia.com/investor/finansiella-rapporter/. In the report, CEO Ulrika Warpman Berglund comments: “2025 was the year in which Oxcia secured its first collaboration agreement with a global pharmaceutical company, as well as ODD from the two largest regulatory authorities.” The Annual General Meeting will be held on June 17, 2026, 16:30, at Fogdevreten 2, Solna.

Patent approval for OXC-201 now also secured in Canada

Oxcia is pleased to announce that the patent for OXC-201, Oxcias potential breakthrough approach for the treatment of IPF (idiopathic pulmonary fibrosis), has now also been approved in Canada. Canada is a key market. Like other IPF markets it is displaying good growth, driven by an ageing population, improved clinical recognition and higher and earlier diagnostic rates. The patent is already approved in the US, Japan and China. The patent application is pending in Europe (EPO - European Patent Organization). The patent is valid until March 2039. As previously communicated, the EIC (

OXC-101 for AML accepted to be presented at EHA

Oxcia AB is pleased to announce that the abstract “Interim results of the phase I/II study investigating karonudib in patients with refractory hematological malignancies paired with ex-vivo precision screen drug sensitivity screening” has been selected by the European Hematological Association (EHA) Scientific Program Committee for a poster presentation during the EHA2026 Congress. The congress takes place in Stockholm this year, June 11-14[th]. Stefan Deneberg, Principal Investigator of the clinical study and Austin Smith, Oxcia’s Chief Medical Officer, will present the interim results.

OXC-101 as a novel therapy in canine blood cancer will be presented at AACR

In a collaboration with SLU and Karolinska Institutet, Oxcia’s mitotic MTH1 inhibitor OXC-101 is investigated in a pilot clinical study in canine lymphoma and hemangiosarcoma. The early clinical results are presented by Dr. Kumar Sanjiv at the American Association for Cancer Research (AACR) annual meeting 19-22 April, 2026. The title of the presentation is: “OXC-2101 (karonudib) in canine lymphoma and hemangiosarcoma: Safety, early efficacy and translational potential” (Poster Number 7913) and will be presented Wed 22 April 2026.

Oxcia welcomes new Scientific Advisory Board for OXC-201

Oxcia is pleased to announce that three leading international experts in pulmonary fibrosis and clinical development have been recruited to its newly formed Strategic Advisory Board (SAB) in Idiopathic Pulmonary Fibrosis (IPF). These distinguished advisors will provide strategic guidance and scientific expertise across key areas, including disease pathology and manifestations, clinical trial design, patient selection, data interpretation, and identification of unmet medical needs. Their insights will play a critical role in advancing Oxcia’s mission to develop innovative therapies for

Oxcia compounds demonstrate antiviral activity

In a pre-clinical study, OXC-201 (TH5487) and its analogue TH6744 show antiviral activity and reduce ZIKV (Zika virus)-induced microcephaly in a chicken embryo model.  Microcephaly is a neurological condition in which an infant's head is much smaller than the heads of other children of the same age. They both demonstrated an effective therapeutic window and were safe and non-teratogenic. The treatment reverses ZIKV-induced neurotoxicity. The results of the study were recently published in Biochemical and Biophysical Research Communications 

EMA approves ODD for OXC-101 in AML

Earlier this spring, Oxcia's drug candidate OXC-101 received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia. Now, the European Medicines Agency (EMA) has also granted OXC-101 ODD approval for European markets.This approval significantly strengthens Oxcia's position, both from a strategic, regulatory and commercial standpoint, according to Oxcia’s CEO Ulrika Warpman Berglund: -These dual approvals give us up to 10 years of market exclusivity in the EU and 7 years in the US, accelerated regulatory processes and

Scientific progress in Psoriasis Research with OXC-101

A new preclinical study shows promising results for OXC-101 (TH1579) as a treatment for psoriasis. The study was conducted in collaboration with Professor Charlotta Enerbäck at Linköping University and Oxcia. Charlotta Enerbäck is professor of dermatology at Linköping University, clinical active, belongs to several advisory boards in psoriasis and is a board member of the European Dermatology Forum.Topical application of OXC-101 effectively inhibits several hallmarks of psoriasis, including keratinocyte hyperproliferation and infiltration of IL-17-producing γδ-T cells. The levels of key

Potential for OXC-101 as a novel therapy for ovarian cancer

A new article published in Experimental Hematology & Oncology by Mayo clinic (USA), Karolinska institutet, and Oxcia AB, shows that OXC-101, a mitotic MTH1 inhibitor, kills ovarian cancer independent of platinum sensitivity.The standard of care therapy for ovarian cancer consists of platinum drugs, e.g. carboplatin. However, the majority of ovarian cancer patients eventually develops resistance to platinum drugs, which is associated with a one-year median survival as current treatments do not work satisfactorily at this stage. Thus, the need for new therapies is high. A therapy that kills

Oxcia enters a research collaboration with LEO Pharma to explore OXC-101 in medical dermatology

Oxcia today announces that it has entered into an early research collaboration with LEO Pharma to explore OXC-101 in topical formulations for medical dermatology indications including psoriasis.Oxcia is developing an oral product, OXC-101, mainly for treatments of cancer. In one of Oxcia's clinical trials, a cancer patient with plaque psoriasis experienced significant improvement in the disease during OXC-101 treatment, indicating that OXC-101 might also have potential in skin diseases, as previously seen in pre-clinical models. OXC-101 is a mitotic MTH1 inhibitor with biological rationale

New findings show OXC-101 may be effective against allergic asthma

OXC-101 is under development for cancer treatment as the main indication, but data suggest that it may also have an effect in autoimmune T-cell driven diseases. Earlier in the year we reported on the promising data for psoriasis. Now, promising effects of OXC-101 in allergic asthma have recently been reported. One of the most common chronic inflammatory airway diseases is asthma, affecting around 300 million individuals worldwide. There is still a need for new pharmacological approaches to modulate the dysregulated airway inflammation in allergic asthma, not least to avoid side-effects

OXC-101 has been granted ODD status by the FDA in AML

The FDA (the United States Food and Drug Administration ) has granted ODD (orphan drug designation) to OXC-101 as a potential treatment option for patients with AML (acute myeloid leukemia).OXC-101 is Oxcia’s lead clinical candidate, a first-in class mitotic MTH1 inhibitor with a unique dual mechanism of action. In short, OXC-101, fights cancer by taking advantage of one of the Achilles heels of cancer cells - the high endogenous oxidative stress and DNA damage. In preclinical studies, OXC-101 significantly prolongs survival and reduces tumor growth in AML disease models. Clinical Phase

Oxcia appoints Eva Sjökvist Saers as Chairman of the Board

Eva Sjökvist Saers has been appointed as the new Chairman of the Board of Directors of Oxcia AB (publ). Oxcia AB has developed the technology platform O2-DDR and is developing new treatments for several serious diseases with the aim of improving and saving lives.Oxcia AB is a leader in research and development on the use of DNA damage and damage responses caused by oxygen, so-called oxidative damage. With its O2-DDR technology platform, Oxcia aims to develop new treatments for e.g. cancer and inflammation to improve and prolong lifes. Eva Sjökvist Saers has worked on Oxcia's Board of

Professor Helleday presents new data on OXC-101 for psoriasis

At the 13th Uppsala University Symposium on Pharmaceutical Profiling in Drug Discovery and Development, Professor Thomas Helleday presents new data on OXC-101, Oxcia’s mitotic MTH1 inhibitor, in psoriasis – a new indication for the project. OXC-101 is developed for cancer treatment, but in this research Oxcia has found interesting data that indicate potential for treatment of autoimmune disorders. Exploratory research is presently carried out in psoriasis.  There is substantial scientific rational for its use in psoriasis. As in cancer, oxidative stress plays an important role and MTH1 is

Oxcia will present at the BioStock Life Science Summit, November 20

The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21. CEO Ulrika Warpman Berglund will present Oxcia to specialist life science investors and potential partners.The Summit connects innovation and capital, providing small-to-medium size Nordic companies from a wide range of therapeutic areas the platform and opportunity to make their case to both Swedish and international investors as well as top-level potential partners in a unique boutique setting.    Date: November 20 Time: 11:05 Location: Auditorium at Medicon Village, Lund Read

Oxcia is focusing the development of OXC-101 on hematological cancers

Following a strategy and data review, Oxcia has chosen to re-prioritize the clinical development of OXC-101 from solid tumors to hematological cancers, specifically acute myeloid leukemia (AML). The preclinical program for OXC-101 has shown good results in both AML and other forms of hematological cancers, and data to date from the phase I/II study MAATEO confirm the previous results. Oxcia has initiated an expansion part of the MAATEO study in patients with refractory/relapsed AML (R/R AML), where OXC-101 is administered in combination with idarubicin (an anthracycline). - The first AML

New publications in peer-reviewed scientific journals support the potential for OXC-101 as a novel anti-cancer therapy

OXC-101 shows promise in enhancing the effectiveness of immune checkpoint inhibitors. The article published in Oncogenesis by Helleday laboratory, Karolinska Institute, and Oxcia team suggests that the mitotic MTH1 inhibitor OXC-101 (TH1579) has the potential to enhance the effectiveness of immune checkpoint inhibitors (ICI) in cancer treatment. This is achieved by influencing immune checkpoint-related proteins and pathways (1). The researchers discovered that treatment with OXC-101 leads to an increase in PD-L1 expression and inflammatory response in cancer cell lines. This finding may

Patent approval now also secured in the US, the largest IPF market

Following the recent patent application approvals in Japan and China, the patent (composition of matter) for OXC-201, Oxcias potential breakthrough approach for the treatment of IPF (idiopathic pulmonary fibrosis), has now also been approved in the largest market, the US. The US represents 57% of the prevalence and incidence of IPF in the 7 major markets and as much as 82% of the market value. The patent is valid at least until 2040. Additional national and regional patent applications are pending in Europe (EPO - European Patent Organization) and Canada. As previously communicated,

Another key milestone for OXC-201 – patent approval in China

Following the recent patent application approval in Japan, the patent for OXC-201, Oxcias potential breakthrough approach for the treatment of IPF (idiopathic pulmonary fibrosis), has now also been approved in China. China and Asia in general are major markets for OXC-201. Asia is estimated to have the largest number of cases of pulmonary fibrosis in the world. Additional national and regional patent applications are pending in the US, Europe (EPO - European Patent Organization) and Canada. As previously communicated, the EIC (European Innovation Council) awarded Oxcia AB in early

Oxcia AB Publishes Year-End Report for 2023

Fourth quarter (October-December 2023) · Operating loss totaled SEK -5,741,054 (-8,972,042). · Loss for the period totaled SEK -5,393,601 (-8,912,366). · Cash flow from operating activities totaled SEK -5,064,247 (-9,565,926). · Earnings per share before dilution totaled SEK -0.23 (-0.41). · Earnings per share after dilution amounted to SEK -0.23 (-0.41). · Proposed dividend of SEK 0.00 per share (0.00). Period (January-December 2023) · Operating loss totaled SEK -33,658,614 (-32,280,497). · Loss for the period totaled SEK -32,608,036 (-32,220,821). · Cash

Oxcia AB presents positive effects of OXC-201 in lung tissue from patient with Idiopatic Pulmonary Fibrosis

Oxcia presents new preclinical data on OXC-201 at the 7th IPF summit in Boston, September 19-21 and European Respiratory Society (ERS) International Congress 2023 September 9–13.  Lung tissue from IPF patients express high levels of several fibrotic biomarkers. Treatment with clinically relevant doses of OXC-201 demonstrated robust dose-dependent reduction of a number of the most important fibrosis-related biomarkers such as TGF-ß and collagen. These data correlate well with results from previous preclinical models, supporting OXC-201 as a potential treatment for IPF.   Christina

Oxcia AB (publ) publishes interim report for the second quarter 2023

Oxcia AB (publ) Interim report 1 January- 30 June 2023   Second quarter (April-June 2023) · Operating loss totaled SEK -6 937 299 (-7 068 278) · Loss for the period totaled SEK -6 600 725 (-7 068 278) · Cash flow from operating activities totaled SEK 395 205 (-5 963 346) · Earnings per share before dilution totaled SEK -0,31 (-0,33) · Earnings per share after dilution amounted to SEK -0,31 (-0,33) Period (January-June 2023) · Operating loss totaled SEK -23 503 674 (-12 381 412) · Loss for the period totaled SEK -23 051 192 (-12 381 412) · Cash flow

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe